Form 4: Cartesian Therapeutics Chief Scientific Officer Reports Stock Transactions
SEC Form 4 Filing
Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, reported the acquisition and disposal of company stock and stock options on November 14th and 15th, 2024.
Summary
- Christopher M. Jewell, the Chief Scientific Officer of Cartesian Therapeutics, engaged in multiple transactions involving the company's stock.
- On November 14, 2024, Jewell acquired 36,050 shares of common stock at $3.23 per share through the exercise of stock options.
- On the same day, Jewell sold 18,550 shares at a weighted average price of $16.341 and 17,500 shares at a weighted average price of $17.0185.
- On November 15, 2024, Jewell acquired 16,065 shares of common stock at $3.23 per share through the exercise of stock options.
- Also on November 15, 2024, Jewell sold 16,065 shares at a weighted average price of $17.0615.
- These transactions resulted in a change in Jewell's holdings of Cartesian Therapeutics common stock and stock options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't indicate any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders who trade their company's stock. It provides transparency into the transactions of key personnel.
Comparison to Industry Standards
- Form 4 filings are a standard practice for publicly traded companies in the United States, ensuring transparency of insider trading activities.
- The reported transactions are typical for executives who hold stock options and may exercise them for profit or diversification purposes.
- The weighted average sale prices are within a reasonable range for the stock, indicating normal market activity.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the volume of shares traded.
- Shareholders are informed about the insider trading activity, which promotes transparency.
Key Dates
| Date | Description |
|---|---|
| 11/13/2023 | Cartesian Therapeutics acquired Old Cartesian. |
| 04/08/2024 | Options previously exercisable for Series A Preferred Stock became exercisable for Common Stock. |
| 11/14/2024 | Chief Scientific Officer exercised options and sold shares. |
| 11/15/2024 | Chief Scientific Officer exercised options and sold shares. |
| 11/18/2024 | Form 4 filing date. |
| 01/15/2033 | Expiration date of stock options. |
| 06/16/2025 | Date when all stock options become fully exercisable. |
Keywords
stock options, insider trading, common stock, stock sale, stock acquisition, Cartesian Therapeutics, Form 4, Christopher M. Jewell
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.